ArticleCancer innovation2025
Coexistent Pulmonary Tuberculosis and Lung Cancer: An Analysis of Incidence Trends, Financial Burdens and Influencing Factors.
Article in Cancer innovation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Clinical characteristics and surgical outcomes of uniportal video-assisted thoracoscopic surgery for lung cancer patients with concomitant pulmonary tuberculosis: a retrospective cohort study.Journal of thoracic disease · 2026Article
- Multidrug-resistant tuberculosis (MDR-TB) in people living with HIV: Clinical issues, therapeutic challenges and perspectives in sub-Saharan Africa. A narrative review.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Review
- Comorbidity of chronic obstructive pulmonary disease and pulmonary tuberculosis: a bibliometric analysis (2011-2025) with narrative review.Journal of thoracic disease · 2026Article
- Neutrophil-specific transcriptomic profiling reveals a novel signature for active tuberculosis diagnosis.Microbiology spectrum · 2026Article
- Development and validation of a habitat-based computed tomography radiomics model for differentiating isolated lung cancer, isolated tuberculoma, and coexistence of tuberculosis with lung cancer: a dual-center retrospective study.Translational lung cancer research · 2026Article
- Development and validation of a diagnostic radiomics model for the differential diagnosis of coexistent tuberculosis and lung cancer versus isolated lung cancer.Journal of thoracic disease · 2025Article
- Establishment and validation of a convenient and efficient screening tool for active pulmonary tuberculosis in lung cancer patients based on common parameters.Therapeutic advances in medical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis (TB) and lung cancer (LC) are both major global health threats. However, coexistent pulmonary TB and LC (TBLC) is a unique condition for which incidence trends and risk factors have not been fully defined. Methods: We retrospectively reviewed the medical records of patients with TBLC and LC alone between 2010 and 2022 at Beijing Chest Hospital, the standard authority for the diagnosis and treatment of TB and LC in China. The cumulative incidence rate (CIR) of TBLC was calculated as the number of new TBLC cases/number of LC cases at risk per 100,000 annually. The comparative incidence rate ratio (IRR) was estimated to be the TB incidence in LC patients/TB incidence in the general population. Logistic regression was used to explore risk factors for TBLC. Results: The CIR of TBLC has rapidly increased each year since 2014 and reached 7027 per 100,000 LC patients in 2022. Patients with LC had a higher risk of developing active TB than the general population (IRR = 25.21, 95% confidence interval [CI]: 21.54-29.89). Medical expenditure per patient was 100.60 thousand yuan for those with TBLC and 105.60 thousand yuan for patients with LC ( Conclusions: There has been a rise in the incidence of coexistent TBLC and a concomitant increase in its financial burden in China that deserves more awareness and attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.